Navigation Links
MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting

ional multi-agent chemotherapy compared to those who received chemotherapy together with Gliadel Wafer were presented in a poster discussion on Monday June 4, 2007. Eighty-five patients with primary glioblastoma multiforme received surgery with

(n=36) or without (n=49) Gliadel implantation followed by radiotherapy and concurrent temozolomide (TMZ) plus one year of adjuvant rotational multi-agent chemotherapy (lomustine (CCNU), TMZ, and irinotecan), consisting of two cycles of each agent. After a median follow-up of

132 weeks, the group that received Gliadel had an extended median survival of 89.4 weeks (95% CI, 65.1- (Infinity)) compared to 72.7 weeks (95% CI, 57.7-84.3) for patients who did not receive Gliadel.

One- and 2- year survival rates were also increased with the addition of Gliadel (81% vs. 67% and 44% vs. 27%, respectively). A Cox proportional hazards model accounting for the effects of the Recursive Partitioning Analysis (RPA) class was performed, and the effect of Gliadel treatment on survival was found to approach significance (pless than 0.055). Adverse events were similar in patients treated with or without Gliadel and included thrombocytopenia, leukopenia, seizures, fatigue, and gastrointestinal.

Irofulven

Results of a Randomized Phase 2 Trial of Irofulven in Hormone Refractory Prostate Cancer (HRPC) Patients who Failed First-line Docetaxel Treatment

Updated results of a randomized, 3-arm phase 2 study of irofulven

+ prednisone +/- capecitabine compared to mitoxantrone + prednisone in

patients with HRPC were presented in a poster discussion on Saturday, June 2, 2007. A total of 137 patients with documented resistance to first-line treatment with docetaxel were stratified by presence or absence of disease related pain at study entry and assigned to treatment in a 2:2:1 manner (i.e. 4/5 patients received an irofulven-containing regimen). Although the study was not designed for a statistical compa
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:8/21/2014)... Aug. 21, 2014 CVS Caremark Corporation (NYSE: ... Reference Yields and consideration payable in connection with its previously ... 7, 2014 for (1) any and all of its 6.250% ... (2) up to a maximum amount of its 6.125% Senior ... Senior Notes due 2017 (collectively, the "Maximum Tender Offer Notes" ...
(Date:8/21/2014)... HOUSTON , Aug. 21, 2014 ... innovation in paediatric medicine by awarding the three ... Paediatric Formulation initiative (EuPFI) conference . The ... 17 – 18 in Athens, Greece ... by pharmacy students and professionals, from which three ...
(Date:8/21/2014)... , Aug. 21, 2014   Royal Philips ... today announced it has received 510(k) clearance from ... its precision planning application for Transcatheter Aortic-Valve Implantation ... application provides interventionalists with pre-procedural, high-precision positioning to ... TAVI planning application is available as part of ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3
... MONICA, Calif., May 8, 2012 Reprints Desk, Inc., ... and first sale of its new mobile-web application ... iPads, mobile devices, product websites, and portals for ... Article Viewer for use by companies in Pharmaceuticals, Biotechnology, ...
... PHILADELPHIA, May 8, 2012  The new prescription sleep aid ... and only prescription sleep aid approved by the U.S. ... insomnia when a middle-of-the-night awakening is followed by difficulty ... four hours of bedtime remaining before the planned time ...
Cached Medicine Technology:Medical Reprints Deployment on iPads and Websites Made Easier with New ePrints Mobile-Web App from Reprints Desk 2Medical Reprints Deployment on iPads and Websites Made Easier with New ePrints Mobile-Web App from Reprints Desk 3Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 2Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 3Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 4Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 5Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 6
(Date:8/21/2014)... Strongly influenced by their self-interest, ... there are no consequences, researchers in Georgia State ... This could imply that humans are less concerned ... researchers said. Their findings are published in the ... of unfairness is affected by their self-interest, indicating ...
(Date:8/21/2014)... August 21, 2014 Local agencies in ... larger discounts for specific protection plans, according to released ... consumers to quote life insurance from local agencies using ... local agents that appear inside of the national system ... method of price reviews this year. Adults who enter ...
(Date:8/21/2014)... The “Proteomics Market by Technology (Protein ... Plasmon Resonance, X-ray Crystallography) - Instruments, Reagents & ... studies the major market drivers, restraints, and opportunities ... of the World (RoW) , Browse 138 market ... and in-depth TOC on “Proteomics Market by Technology ...
(Date:8/21/2014)... Vegas, NV (PRWEB) August 21, 2014 ... the Association for Packaging and Processing Technologies. They ... It’s the view into a whole new world ... of engaged attendees, interactive education, and the latest ... lifecycle solutions from exhibitors. This year at Pack ...
(Date:8/21/2014)... 21, 2014 Today, Zane Benefits, the ... the premium tax credits in 2015. , According to ... part of the Affordable Care Act (ACA), premium tax ... individual health insurance through the Health Insurance Marketplaces. , ... and the amount of the tax credits, updated for ...
Breaking Medicine News(10 mins):Health News:Influenced by Self-Interest, Humans Less Concerned About Inequity To Others, Researchers Find 2Health News:Influenced by Self-Interest, Humans Less Concerned About Inequity To Others, Researchers Find 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 5Health News:Absolute I&D Provides Discounted Labor for Pack Expo Chicago 2
... of U.S. patents, has expanded its free offerings, providing access ... host of other improvements, making it even easier to find and ... ... 9, 2008 -- PatentStorm , the searchable website of millions ...
... and lay the groundwork for Phase 2 trials ... Leukemia (AML) settings , , ... Pharmaceuticals today announced that a Phase 1 dose ... the recommended dose for Phase 2 studies and ...
... today that a total of,20 U.S. and global abstracts ... presentation at the 2008 San Antonio,Breast Cancer Symposium (SABCS) ... breast cancer to be presented on Sunday, December,14, by ... Two U.S. abstracts to be presented ...
... Dec. 9 Frost & Sullivan, a global ... recently held Manufacturing Summit, hosted the India Manufacturing ... Bangalore. Instituted in 2004, the awards aim to ... manufacturing capabilities and acknowledge the best facilities in ...
... an extended period of time when parents grappling with the natural grief ... 10 ways relatives and friends can make the holidays just a little ... Friends, the world,s largest self help support organization with more than 600 ... ...
... leading FDA software development company - provides medical device makers with ... technical report, available now. , ... (PRWEB) December 9, ... software development company Full Spectrum informs medical device ...
Cached Medicine News:Health News:PatentStorm Releases U.S. Patent Applications and Other Features 2Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 2Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 3Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 4Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 5Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 2Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 3Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 2Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 3Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 4Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 5Health News:Ten Ways You Can Help a Family During the Holidays After a Child Dies 2Health News:Aimed at Medical Device Makers, FDA Software Development Company Full Spectrum Releases Free Technical Report on Software Protection Technology 2
... 2.0 is a reagent and probe system ... The high throughput plate based system is ... provides a unique approach for RNA detection ... using branched DNA (bDNA) technology. Branched DNA ...
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
...
Medicine Products: